{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:03:53Z","timestamp":1756339433605,"version":"3.44.0"},"reference-count":14,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Hydroa vacciniforme lymphoproliferative disorders (HVLPD) fall within the clinical spectrum of chronic active epstein barr virus (EBV) disease (CAEBVD), ranging from localised and\/or indolent forms (classic HVLPD) to systemic disease with fever, hepatosplenomegaly and lymphadenopathy (systemic HVLPD). A preadolescent male with 47XYY, multicystic dysplastic kidney, autism spectrum disorder and Attention-deficit\/hyperactivity disorder (ADHD) presented with photodistributed non-pruritic, non-painful necrotic papulovesicles accompanied by non-febrile intermittent fatigue and lymphadenopathy. The patient had a history of EBV pneumonia in infancy confirmed by CT scan and was later diagnosed with CAEBV. Despite presenting without the typical risk factors of East Asian or Latin American background, young adulthood onset and long-standing classic HVLPD, the patient\u2019s CAEBVD, systemic symptoms and gamma\u2013delta T-cell clonal expansion were consistent with a diagnosis of systemic HVLPD. Systemic HVLPD is high-risk for malignant transformation, requiring close follow-up to evaluate for HV-like T-cell lymphoma. Due to the patient\u2019s risk factors and findings consistent with systemic HVLPD, the patient is regularly surveilled for progression to lymphoma.<\/jats:p>","DOI":"10.1136\/bcr-2024-261993","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T02:15:17Z","timestamp":1735352117000},"page":"e261993","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic hydroa vacciniforme lymphoproliferative disorder in a patient with chronic active EBV infection"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1767-1137","authenticated-orcid":false,"given":"Katie R","family":"Xu","sequence":"first","affiliation":[{"name":"Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonal","family":"Shah","sequence":"additional","affiliation":[{"name":"Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Pediatric Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Rohr","sequence":"additional","affiliation":[{"name":"Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Case Western Reserve University School of Medicine, Cleveland, Ohio, USA"},{"name":"Dermatology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"2025082703555480000_17.12.e261993.1","unstructured":"Rice AS , Bermudez R . StatPearls. StatPearls Publishing; Hydroa Vacciniforme, 2023."},{"key":"2025082703555480000_17.12.e261993.2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239314","article-title":"Hydroa Vacciniforme and Hydroa Vacciniforme-Like Lymphoproliferative Disorder: A Spectrum of Disease Phenotypes Associated with Ultraviolet Irradiation and Chronic Epstein-Barr Virus Infection","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025082703555480000_17.12.e261993.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2025082703555480000_17.12.e261993.4","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1111\/1346-8138.16842","article-title":"Diagnostic and disease severity determination criteria for hydroa vacciniforme lymphoproliferative disorders and severe mosquito bite allergy","volume":"50","author":"Hirai","year":"2023","journal-title":"J Dermatol"},{"key":"2025082703555480000_17.12.e261993.5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1159\/000530607","article-title":"Clinicoprognostic Study of Hydroa Vacciniforme-like Lymphoproliferative Diseases: A Systematic Review","volume":"239","author":"Kim","year":"2023","journal-title":"Dermatology"},{"key":"2025082703555480000_17.12.e261993.6","doi-asserted-by":"crossref","unstructured":"Zhang C , Chang L , Yang X , et al . n.d. Severe atypical hydroa vacciniforme-like lymphoproliferative disorder in a patient with hyper IgE syndromes due to DOCK8 gene mutation. IJDVL 89:874\u20137. doi:10.25259\/IJDVL_409_2022","DOI":"10.25259\/IJDVL_409_2022"},{"key":"2025082703555480000_17.12.e261993.7","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3181c036de"},{"key":"2025082703555480000_17.12.e261993.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921"},{"key":"2025082703555480000_17.12.e261993.9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/ijd.16273","article-title":"The genomic and proteomic landscape in oral lichen planus versus oral squamous cell carcinoma: a scoping review","volume":"61","author":"Xie","year":"2022","journal-title":"Int J Dermatol"},{"key":"2025082703555480000_17.12.e261993.10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40257-018-0365-6","article-title":"Recent Developments in the Diagnosis and Management of Photosensitive Disorders","volume":"19","author":"Nahhas","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025082703555480000_17.12.e261993.11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2019.01.011","article-title":"Hydroa vacciniforme-like lymphoproliferative disorder: Clinicopathologic study of 41 cases","volume":"81","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025082703555480000_17.12.e261993.12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.14044","article-title":"Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents","volume":"173","author":"Pillai","year":"2016","journal-title":"Br J Haematol"},{"key":"2025082703555480000_17.12.e261993.13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2147\/IDR.S402040","article-title":"Clinical and Pathological Features of Hydroa Vacciniforme-Like Lymphoproliferative Disorder Along with Risk Factors Indicating Poor Prognosis","volume":"16","author":"Chang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2025082703555480000_17.12.e261993.14","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/bloodadvances.2020001451","article-title":"Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification","volume":"4","author":"Yonese","year":"2020","journal-title":"Blood Adv"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-261993","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:56:06Z","timestamp":1756292166000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-261993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,27]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bcr-2024-261993"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-261993","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}